Jamming of the Hikurangi Plateau (large igneous province) subduction, within the Chatham Rise convergent margin of Gondwana at circa 105Ma, led to offset and rotation of the convergent margin before subduction ceased in the New Zealand region at circa 100Ma. The southern limit of the plateau, following leading slab break off, is highlighted by a lineament of prominent horst blocks in the southern Bounty Trough. Subduction jamming of the Gondwana margin, and accompanying compression of the onshore margin and/or extension of the offshore margin, has led to two 60km left-lateral SSE offsets of the Chatham Rise convergent margin at the coast and in inland Canterbury. Recognition of the onshore Chatham Rise using the gravity data also highlights the correlation of the inland Chatham Rise and central South Island seismicity. In a similar manner to the rotation of Cretaceous spreading-ridge and transform-fault fabric adjacent to the Osbourn Trough spreading ridge, the convergence direction at the Gondwana margin was rotated anticlockwise to N-S between 105 and 100Ma. Most of this rotation has been accommodated by offshore extension and margin offset. The divergence between the anticlockwise rotation of offshore crustal structure and the jammed onshore margin led to the development of the Great South Basin at 105-100Ma. Further offshore in the Bounty Trough, extensional zones, formed between crustal blocks rotated to adjust to a changed Cretaceous direction of subduction, are evident in gravity and seismic profiles.

Allogeneic SCT for myeloma may be curative for young patients, but its role remains controversial because of a reported high TRM in some series. Since 1991, we have performed 25 allografts for myeloma using fully matched sibling donors. Of the 18 evaluable patients, 13 achieved CR at a median time of 2.5 months post-transplant. The five patients who were not in CR when assessed at 3 months received a short course of alpha-interferon and four subsequently achieved CR with this approach at a median of 82 days. One patient who failed to respond to IFN went on to achieve CR after four doses of DLI therapy, thus giving an overall CR rate of 72%. Seven patients have relapsed at a median of 4.7 years post-transplant (range 1.38-7.7 years) including two patients who had received IFN therapy. In five of these cases, relapse has been as a localised area of bone disease or isolated plasmacytoma with no evidence of marrow involvement by trephine biopsy or molecular analysis. All patients with localised relapse were treated with local radiotherapy +/-DLI and four are currently disease free despite two patients having had further treatment for a second localised lesion. Six patients died of TRM (24%) and the OS at 8 years is currently 69% with an EFS of 26%. These results suggest that allogeneic SCT for myeloma can be carried out with an acceptable TRM and a high CR rate. However, late relapses as localised disease may be a frequent finding and may represent foci of myeloma not eradicated by the conditioning. The use of pretransplant MRI scanning and top-up radiotherapy to involved areas may be useful in preventing this type of relapse.

A 32-year-old man with CML in second chronic phase developed primary graft failure following matched unrelated donor transplantation using cryopreserved marrow cells. He was successfully regrafted within 60 days from a second fully matched donor using a non-myeloablative conditioning regimen, with minimal toxicity. He remains in complete haematological, cytogenetic and molecular remission 2 years after second transplant. We believe that reduced intensity or ‘mini-transplants’ may be preferable for patients requiring second allografts which are usually associated with a high transplant-related mortality. Bone Marrow Transplantation (2001) 27, 547–549.

This study compared CD34 selection procedures using the CellPro CEPRATE and the Baxter Isolex 300 systems. Thirty-two procedures were performed, 19 CEPRATE and 13 Isolex. Median starting CD34 percentages were (CEPRATE/Isolex) 0.80% (range 0.24%-7.73%) and 0.85% (range 0.27%-10.17%), respectively (p = 0.788). After selection, there was a highly significant difference in purity of the product (CEPRATE/Isolex), 54% and 82% respectively (p < 0.0001). There was no significant difference in median recovery (CEPRATE/Isolex), 43% and 50%, respectively (p = 0.383). The starting CD34 percentage influenced the purity of the final product, and at high and low starting percentages, the Isolex produced superior purity. Improved efficacy of T cell depletion was observed with the Isolex, a median log depletion of 3.4 compared with 2.9 for the CEPRATE system (p = 0.012). In conclusion, the Isolex 300i produced a significantly higher purity CD34+ fraction, even at starting CD34+ levels of <0.5%, with no significant difference in recovery when compared with the CEPRATE system. The associated log T cell depletion is significantly improved with the Isolex system, with possible implications for use in CD34-selected allogeneic transplants.

The paper discusses the problem of ambiguity resolution in the range and velocity dimensions of an adaptive radar. In Part 1, the basic ambiguity problem is introduced, and the principles of ambiguity resolution are developed for the case of a radar which is ambiguous in one dimension only. In Part 2, the simultaneous resolution of ambiguities in range and velocity is considered. Part 3 discusses ...

A novel radar system is proposed which effectively and simply combines the respective merits of pulsed a.m. and f.m. c.w. Doppler radar, by the use of a combined a.m. and f.m. waveform. Simple waveform changes permit the radar to be adapted to suit a wide range of operational requirements. This type of radar would require computer control for its full exploitation, and it is assumed that its principal application will be in fully automatic track-while-scan radars. The operation of the system in its various modes is described, and some technical aspects of the implementation of the system are discussed.